Minimal Residual Disease MRD Monitoring for Multiple Myeloma Test
Introduction to MRD Monitoring
The Minimal Residual Disease (MRD) Monitoring for Multiple Myeloma Test is a specialized diagnostic assay that plays a pivotal role in the management of multiple myeloma, a type of blood cancer. This test helps in detecting the presence of small numbers of cancer cells that may remain in the body after treatment, which can be crucial for determining the effectiveness of therapy and guiding future treatment decisions.
What the Test Measures
This test employs advanced flow cytometry techniques to measure specific markers on blood cells, including:
- CD45
- CD19
- CD20
- CD27
- CD38
- CD138
- CD56
- CD117
- CD200
- CD81
- Kappa
- Lambda
By analyzing these markers, the test can detect residual disease that traditional imaging techniques might miss.
Who Should Consider This Test?
This test is recommended for patients diagnosed with multiple myeloma, especially those undergoing treatment. It is particularly important for patients experiencing:
- Recent chemotherapy
- Symptoms of relapse
- Changes in blood counts or overall health
Patients on anti-CD38 therapy should also consider this test to monitor their disease effectively.
Benefits of Taking the Test
- Identifies residual cancer cells post-treatment, allowing for timely intervention.
- Helps oncologists tailor treatment plans based on individual patient needs.
- Provides peace of mind for patients regarding their cancer status.
Understanding Your Results
The results of the MRD Monitoring test will indicate the level of residual disease present. A lower level of residual disease typically suggests a better response to treatment and may influence future therapeutic decisions. It is essential to discuss your results with your oncologist for personalized guidance.
Test Pricing
| Test Name | Discount Price (KSh) | Regular Price (KSh) |
|---|---|---|
| Minimal Residual Disease MRD Monitoring for Multiple Myeloma | 32,000 | 50,000 |
Sample Collection and Pre-Test Instructions
Sample type: 3 mL (1 mL min.) Bone Marrow (first pull aspirate) in 1 Green Top (Sodium Heparin) tube. Mix thoroughly & Ship immediately at 18-22°C or at 2-8°C. DO NOT FREEZE.
Mandatory information includes:
- Sample time point (Chemotherapy time points)
- Previous diagnostic immunophenotype report
- Clinical history, especially if the patient is on anti-CD38 therapy
- Original TRF
- Date and time when the sample was drawn
- 1 or 2 unstained BMA smears to be made at the source
Book Your Test Today!
We have branches across Kenya and offer home sample collection services. To book your Minimal Residual Disease MRD Monitoring for Multiple Myeloma Test, please call or WhatsApp us at +254711564616. Don’t wait; take control of your health today!
